ArticleMovement disorders clinical practice2026
Disease-Duration-Specific Percentiles for Prospective Subtyping of Parkinson's Disease: A PPMI-Based Study.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is clinically heterogeneous, with variable progression rates that complicate clinical trial design. The data-driven diffuse malignant (DM), intermediate (IM), and mild-motor predominant (MMP) subtyping model has prognostic value but lacks disease duration-specific thresholds for prospective use in disease-modifying trials.
objectiveTo define year-specific percentile thresholds for key motor and non-motor measures within the first 5 years after diagnosis to enable real-time PD subtyping and assess progression patterns across subtypes.
methodsWe analyzed de-identified PPMI data (downloaded April 22, 2026) from 1030 individuals with idiopathic PD. For each disease year, we computed percentiles for a composite motor score (MDS-UPDRS II + III + PIGD) and non-motor measures (MoCA, RBDSQ, SCOPA-AUT). Thresholds were set at the 75th percentile for motor, RBDSQ, and SCOPA-AUT, and the 25th percentile for MoCA, and applied annually to classify DM-, IM-, and MMP-PD. Subtype stability (years 1-5) and progression were assessed using 25 predefined PPMI milestones. Kaplan-Meier and Cox regression models evaluated time to first milestone.
resultsPercentile thresholds worsened progressively over time, paralleling cohort-level decline. DM-PD prevalence ranged from 19.2-20.5% (IM 41.8-44.4%; MMP 35.1-38.8%). At baseline, clinical measures differed significantly across subtypes. Compared to MMP-PD, DM-PD (HR 3.03; 95% CI: 2.30-3.97) and IM-PD (HR 1.48; 95% CI: 1.19-1.84) showed faster progression.
conclusionsWe establish disease duration-specific percentiles for prospective application of the DM/IM/MMP subtyping model, supporting patient stratification and enrichment in disease-modifying trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.